RCP
DMRA

Remedium Capital Partners’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Remedium Capital Partners’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53M Buy
2,045,473
+1,925,000
+1,598% +$49.5M 18.84% 3
2025
Q4 		$2.77M Buy
+120,473
New +$2.09M 1.63% 6

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Remedium Capital Partners's DMRA Position: Q1 2026 in Review

Remedium Capital Partners increased its Damora Therapeutics, Inc. Ordinary Shares (DMRA) stake by 1,598% in Q1 2026, buying an estimated $49.5M and bringing the position to 2,045,473 shares worth $53M. The position accounts for 18.84% of the portfolio, ranked #3.

Remedium Capital Partners first reported a position in DMRA in Q4 2025 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Remedium Capital Partners held 2,045,473 shares of Damora Therapeutics, Inc. Ordinary Shares worth $53M as of Q1 2026.
  • Remedium Capital Partners bought 1,925,000 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2026, an estimated $49.5M.
  • Damora Therapeutics, Inc. Ordinary Shares made up 18.84% of Remedium Capital Partners's portfolio in Q1 2026, its #3 holding.
  • Remedium Capital Partners first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2025 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Remedium Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.